{
  "patent_number": "US 6531124",
  "country": "US",
  "title": "How to Use Modified Cells to Produce Insulin-Regulating Proteins in the Body",
  "original_title": "In vivo production and delivery of insulinotropin for gene therapy",
  "summary": "A method for taking a patient's own cells, modifying them with DNA to produce GLP-1, and putting them back into the body to treat metabolic conditions.",
  "what_it_does": "This patent describes a gene therapy approach where a patient's own somatic cells (like skin or blood cells) are removed and modified in a lab. Scientists insert a DNA construct that carries instructions for the cell to produce a specific protein, specifically GLP-1 (glucagon-like peptide 1) or its derivatives. These modified cells are then grown into a clonal strain, which means they are multiplied to create a large, consistent population. Finally, these cells are reintroduced into the patient's body, where they act as a living factory to continuously produce the desired protein.",
  "what_it_does_not_cover": [
    "Does not cover direct injection of synthetic GLP-1 drugs like semaglutide or liraglutide.",
    "Does not cover viral-vector gene therapy where DNA is delivered directly into the body without cell removal.",
    "Does not cover the use of embryonic stem cells or germline cells.",
    "Does not cover the production of proteins other than GLP-1 or EPO."
  ],
  "filed": "1999-08-16",
  "granted": "2003-03-11",
  "expires": null,
  "status": "active",
  "holder": "Transkaryotic Therapies Inc",
  "holder_url": "https://patentbrief.org/company/transkaryotic-therapies-inc",
  "inventors": [
    {
      "name": "Michael W. Heartlein",
      "url": "https://patentbrief.org/inventor/michael-w-heartlein"
    },
    {
      "name": "Richard F Selden",
      "url": "https://patentbrief.org/inventor/richard-f-selden"
    },
    {
      "name": "Douglas Treco",
      "url": "https://patentbrief.org/inventor/douglas-treco"
    }
  ],
  "times_cited": 2,
  "tags": [
    "biotech",
    "pharmaceutical"
  ],
  "abstract": "The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) that encodes erythropoietin or an insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP 1)), methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains that express erythropoietin or an insulinotropin, methods of gene therapy, in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells. The present invention includes primary and secondary somatic cells, such as fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial cells, neural cells, formed elements of the blood, muscle cells, other somatic cells that can be cultured, and somatic cell precursors, which have been transfected with exogenous DNA encoding EPO or an insulinotropin that is stably integrated into their genomes or is expressed in the cells episomally.",
  "url": "https://patentbrief.org/patent/us/6531124/xolair-omalizumab",
  "markdown_url": "https://patentbrief.org/patent/us/6531124/xolair-omalizumab/md",
  "google_patents_url": "https://patents.google.com/patent/US6531124",
  "relatedPatents": []
}